Rapidly Progressive Interstitial Lung Disease with Coexisting Anti-MDA5 and Anti-OJ Antibodies Successfully Treated with Intensive Immunosuppression and Plasma Exchange
Abstract
Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis is frequently complicated by rapidly progressive interstitial lung disease, whereas anti-aminoacyl-tRNA synthetase (ARS) antibody-positive interstitial lung disease typically follows a subacute or chronic course and responds to immunosuppressive therapy. The coexistence of anti-MDA5 and anti-ARS antibodies, particularly anti-OJ antibodies, is very rare. We report the case of a 58-year-old man who was double positive for anti-MDA5 and anti-OJ antibodies and developed rapidly progressive interstitial lung disease. The disease continued to progress with triple immunosuppressive therapy; however, the introduction of plasma exchange led to marked clinical and radiological improvements. This case highlights the importance of recognizing the coexistence of antibodies and integrating serological, radiological, and clinical findings to guide timely and appropriate treatment.
Related
- Beyond Ocular Symptoms: Chronic Progressive External Ophthalmoplegia With Coexisting Facial Palsy and T-wave Inversion
- Automated quantitative analysis can support the identification of progressive pulmonary fibrosis in fibrotic interstitial lung disease.
- Staged multi-target therapy for anti-MDA5-positive dermatomyositis-associated rapidly progressive interstitial lung disease: a case report.
- Progressive Interstitial Lung Disease Following Hematopoietic Stem Cell Transplantation for Combined Immunodeficiency: A Novel Homozygous SLC7A7 Variant Suggestive of Lysinuric Protein Intolerance
- Treatment trajectories by radiologic pattern of lung injury in interstitial lung disease with myositis-associated antibodies: a retrospective cohort study
BibTeX
@article{nakatani2026rapidly,
title = {{Rapidly Progressive Interstitial Lung Disease with Coexisting Anti-MDA5 and Anti-OJ Antibodies Successfully Treated with Intensive Immunosuppression and Plasma Exchange}},
author = {Daisuke Nakatani and Hideaki Yamakawa and Keiichi Akasaka and Yoko Machida and Keiichiro Kanai and Tomohiro Oba and Masako Amano and Hidekazu Matsushima},
journal = {Internal Medicine},
year = {2026},
month = nov,
doi = {10.2169/internalmedicine.7090-26},
url = {https://www.jstage.jst.go.jp/article/internalmedicine/65/22/65_7090-26/_article},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Rapidly Progressive Interstitial Lung Disease with Coexisting Anti-MDA5 and Anti-OJ Antibodies Successfully Treated with Intensive Immunosuppression and Plasma Exchange
AU - Daisuke Nakatani
AU - Hideaki Yamakawa
AU - Keiichi Akasaka
AU - Yoko Machida
AU - Keiichiro Kanai
AU - Tomohiro Oba
AU - Masako Amano
AU - Hidekazu Matsushima
PY - 2026
DA - 2026/11/15
JO - Internal Medicine
DO - 10.2169/internalmedicine.7090-26
UR - https://www.jstage.jst.go.jp/article/internalmedicine/65/22/65_7090-26/_article
AB - Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis is frequently complicated by rapidly progressive interstitial lung disease, whereas anti-aminoacyl-tRNA synthetase (ARS) antibody-positive interstitial lung disease typically follows a subacute or chronic course and responds to immunosuppressive therapy. The coexistence of anti-MDA5 and anti-ARS antibodies, particularly anti-OJ antibodies, is very rare. We report the case of a 58-year-old man who was double positive for anti-MDA5 and anti-OJ antibodies and developed rapidly progressive interstitial lung disease. The disease continued to progress with triple immunosuppressive therapy; however, the introduction of plasma exchange led to marked clinical and radiological improvements. This case highlights the importance of recognizing the coexistence of antibodies and integrating serological, radiological, and clinical findings to guide timely and appropriate treatment.
SN - 1349-7235
SN - 0918-2918
ER -